GABORONE, Botswana – Botswana has produced its first batch of antiretroviral (ARV) medicines locally, marking a major development in the country’s efforts to strengthen access to essential healthcare products and reduce dependence on imported medicines.
The medicines were manufactured at Portfolio Pharmaceuticals Botswana’s facility in Phakalane following the successful transfer of production technology from an international manufacturing partner.
The initiative has also involved training local pharmacists, scientists and technicians to manage the manufacturing process, conduct product testing and maintain quality control standards.
Assistant Minister of Health Lawrence Ookeditse said domestic production would help Botswana respond to medicine supply shortages while reducing its exposure to disruptions in international supply chains.
He said the project could also create skilled employment opportunities for Batswana and support the development of local expertise in pharmaceutical manufacturing.
Before the newly produced medicines can be distributed for use, Portfolio Pharmaceuticals must complete the required regulatory procedures in collaboration with the Botswana Medicines Regulatory Authority (BoMRA).
Ookeditse challenged the company to build on the initial production milestone by expanding its manufacturing capacity and exploring opportunities to supply pharmaceutical products to other African markets.
Portfolio Pharmaceuticals Botswana plans to extend local production beyond ARVs to include medicines used in the treatment of chronic conditions.
Leave a comment